News | 02 June 2021
Progress on new ventures key for Aurobindo Pharma: ICICI Securities
Aurobindo has one of the most enduring generics ecosystems among peers
Aurobindo has one of the most enduring generics ecosystems among peers
Revenues from operations for FY21 stood at Rs. 202.38 crore as compared to 167.27 crore, up by 21%
The company has posted net profit of Rs.147.78 crores for the 12 months period ended March 31, 2021
The company's operating revenue for Q4 FY21 was Rs. 330.2 crore
This investment is being made to set up a high speed 400 vials a minute injectable fill line with isolator technology
7.94 crore doses were made available to the states in May 2021
Adjusted PAT declined 18.8% YoY
US revenues were sequentially stable at US$370mn with steady performance in the specialty portfolio
Cadila's ZyCov-D (DNA-based vaccine) is undergoing phase III trials.
The company reported total income of Rs.24774.63 crores during the 12 months period ended March 31, 2021
The company has posted net profit of Rs.1140.01 crores during FY 2020-21
The patients can check to see if the product purchased by them is genuine or not by scratching the surface and verifying the code through the app or the website
It posted net profit of Rs.60.96 crores for the 12 months period ended March 31, 2021
For the year ended March 31, 2021, consolidated revenue was at Rs. 10,943.9 crores as against Rs. 10,641 crores, recording an increase of 2.8% over the previous corresponding period
The company has registered total income of Rs. 3,847 crores for Q4 FY21, up by 3% on a y-o-y basis from Rs. 3,752 crores registered during corresponding period of the previous year
Mucormycosis drug AmphoTLC will be imported from Taiwan by Stelis Biopharma Private Limited (Stelis), the biotech arm of Strides group, and will be launched and distributed in India immediately by Strides
MEK inhibitor compound (LNP3794) developed as part of its oncology pipeline had previously shown pre-clinical activity as a single agent as well as in combination
Dr. Sharvil Patel cites the example of prescriptions being handed over to patients despite unavailability of enough stock of such medicines
It is expected that the drug substance would be available from August 2021 which will be supplied back to Bharat Biotech for producing COVAXIN
Consequently, AstraZeneca India and Sun Pharma have now discontinued the Distribution Agreement signed in 2016 and have entered into a Transition Supply Agreement with effect from 28th May 2021
Subscribe To Our Newsletter & Stay Updated
